Qifang Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qifang Jin has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Ke Shi
Department of Ophthalmology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China
1 shared publicationLeifeng Chen
Jiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China
1 shared publicationQian Wang
Ophthalmic Center, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China
1 shared publicationShiqi Qin
Ophthalmic Center, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China
1 shared publicationWeiqi Wu
Ophthalmic Center, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China
1 shared publicationWenfeng He
Jiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China
1 shared publication
Latest Publications
- 3 March 2026
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 73, 102920
Application of photoresponsive materials in ophthalmology
- 3 March 2026
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 73, 102920
Application of photoresponsive materials in ophthalmology
- Open Access
- 4 July 2018
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 16 (3) , 1663-1670
MicroRNA‑101‑3p inhibits proliferation in retinoblastoma cells by targeting EZH2 and HDAC9
Retinoblastoma is the most frequent intraocular malignant tumor type to occur in childhood. MicroRNA (miR)‑101‑3p has been reported to function as a tumor suppressor in various types of cancer. However, the biological function and underlying mechanisms of miR‑101‑3p in retinoblastoma are largely unknown. In the present study, it was identified that miR‑101‑3p was downregulated in retinoblastoma. MTT and flow cytometry assays demonstrated that ectopic overexpression of miR‑101‑3p significantly inhibited cell viability and cell cycle progression in WERI‑Rb‑1 and Y79 cells. In vivo mouse experiments further confirmed the anti‑proliferative role of miR‑101‑3p in retinoblastoma. Additionally, predictions with TargetScan software indicated that the 3'‑untranslated regions of enhancer of zeste homolog 2 (EZH2) and histone deacetylase (HDAC9) mRNAs are targeted by miR‑101‑3p. Accordingly, a dual luciferase reporter gene assay demonstrated that miR‑101‑3p directly targeted EZH2 and HDAC9 to suppress the proliferation of retinoblastoma cells. Meanwhile, the restoration of EZH2 or HDAC9 expression countered the anti‑proliferative effect of miR‑101‑3p on WERI‑Rb‑1 and Y79 cells. Collectively, these data highlight the role of miR‑101‑3p in the tumorigenesis of retinoblastoma, and indicate its suitability as a novel therapeutic target.
- 4 July 2018
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 16 (3) , 1663-1670
Open AccessMicroRNA‑101‑3p inhibits proliferation in retinoblastoma cells by targeting EZH2 and HDAC9
Retinoblastoma is the most frequent intraocular malignant tumor type to occur in childhood. MicroRNA (miR)‑101‑3p has been reported to function as a tumor suppressor in various types of cancer. However, the biological function and underlying mechanisms of miR‑101‑3p in retinoblastoma are largely unknown. In the present study, it was identified that miR‑101‑3p was downregulated in retinoblastoma. MTT and flow cytometry assays demonstrated that ectopic overexpression of miR‑101‑3p significantly inhibited cell viability and cell cycle progression in WERI‑Rb‑1 and Y79 cells. In vivo mouse experiments further confirmed the anti‑proliferative role of miR‑101‑3p in retinoblastoma. Additionally, predictions with TargetScan software indicated that the 3'‑untranslated regions of enhancer of zeste homolog 2 (EZH2) and histone deacetylase (HDAC9) mRNAs are targeted by miR‑101‑3p. Accordingly, a dual luciferase reporter gene assay demonstrated that miR‑101‑3p directly targeted EZH2 and HDAC9 to suppress the proliferation of retinoblastoma cells. Meanwhile, the restoration of EZH2 or HDAC9 expression countered the anti‑proliferative effect of miR‑101‑3p on WERI‑Rb‑1 and Y79 cells. Collectively, these data highlight the role of miR‑101‑3p in the tumorigenesis of retinoblastoma, and indicate its suitability as a novel therapeutic target.